CD19&CD20 bispecific CAR-T cells therapy(Hebei Taihe Chunyu Biotechnology)

N/A

Report date: 2025/01/13 17:01:50

Base Information

Drug NameCD19&CD20 bispecific CAR-T cells therapy(Hebei Taihe Chunyu Biotechnology)
Drug Alias NameBispecific CAR T cell therapy(Hebei Taihe Chunyu Biotechnology)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy > Dual-target CAR-T cell therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionAnti-CD19Anti-CD20
TargetsB-lymphocyte antigen CD19B-lymphocyte antigen CD20
Therapy Area/IndicationsPrecursor B-Cell Lymphoblastic Leukemia-Lymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesHebei Tahoe Chunyu Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesHebei Tahoe Chunyu Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsPrecursor B-Cell Lymphoblastic Leukemia-Lymphoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A